An Investigation of Small GTPases in relation to Liver Tumorigenesis Using Traditional Chinese Medicine

Tzu-Chieh Hung, Wen-Yuan Lee, Kuen-Bao Chen, Yueh-Chiu Chan, and Calvin Yu-Chian Chen

1 Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2 School of Medicine, China Medical University, Taichung 40402, Taiwan
3 Department of Neurosurgery, China Medical University Hospital, No. 2 Yude Road, North District, Taichung 40447, Taiwan
4 Department of Anesthesiology, China Medical University Hospital, Taichung 40447, Taiwan
5 Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 40402, Taiwan
6 Human Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan

Correspondence should be addressed to Calvin Yu-Chian Chen; ycc929@MIT.edu

Received 25 February 2014; Revised 5 March 2014; Accepted 5 March 2014; Published 19 June 2014

Academic Editor: Chung Y. Hsu

Copyright © 2014 Tzu-Chieh Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, an important topic of liver tumorigenesis had been published in 2013. In this report, Ras and Rho had defined the relation of liver tumorigenesis. Ras and Rho are an important target for liver tumorigenesis [1]. The liver tumorigenesis (or means hepatic carcinoma) is a serious disease in the world, especially in Asia. The main cause of liver tumorigenesis is virus (HBV or HCV) and abnormal eating and habits (smoke, drink, barbecue, raw food, fatigue, and staying up late). The cumulative burden decreases immunity and then makes liver tumorigenesis. The most cases of hepatic carcinoma are found too late to treat and there is no efficient drug that could prevent disease progression which then causes the patient’s death.

1. Introduction

Recently, an important topic of liver tumorigenesis had been published in 2013. In this report, Ras and Rho had defined the relation of liver tumorigenesis. The traditional Chinese medicine (TCM) database has been screened for molecular compounds by simulating molecular docking and molecular dynamics to regulate Ras and liver tumorigenesis. Saussureamine C, S-allylmercaptocysteine, and Tryptophan are selected based on the highest docking score than other TCM compounds. The molecular dynamics are helpful in the analysis and detection of protein-ligand interactions. Based on the docking poses, hydrophobic interactions, and hydrogen bond variations, this research surmises are the main regions of important amino acids in Ras. In addition to the detection of TCM compound efficacy, we suggest Saussureamine C is better than the others for protein-ligand interaction.
CADD to investigate the basics of molecular simulation in drug design centered on structure-based drug design and molecular dynamics [5–8].

Recently, there are more attentions on personalized medicine and biomedicine [9]; then this knowledge could analyze the mutation [10], and cause for special disease [11]. Traditional Chinese medicine (TCM) is a model of personalized medicine. TCM has an important role in Asia, especially in China, Taiwan, Korea, and Japan. The TCM Database@Taiwan (http://tcm.cmu.edu.tw/) [12] is the largest traditional Chinese medicine database in the world. This database contains 2D chemical structures, 3D chemical structures, bioactivity, and molecular information for over 61,000 compounds of traditional Chinese medicinal herbs. Since 2011, there have been successful discoveries of novel lead compounds from the TCM Database@Taiwan for cancer treatment [13–16], pain relief [6], and antivirals [17–19]. With the assistance of the application system of the website [20] and the cloud computing platform [21], the TCM Database@Taiwan could be valuable for TCM application and drug design.

In this study, we screen a possible lead compound against liver tumorigenesis from the TCM Database@Taiwan. We use the computational techniques of docking screening to select ligands. Finally, we apply molecular dynamics (MD) simulation to investigate variations from protein-ligand interactions that may contribute to the evaluation of the effect on Ras inhibition.

2. Materials and Methods

2.1. Data Set. In this research, the molecular simulations platform was using Accelrys Discovery Studio 2.5 (DS 2.5). Amount of 61,000 TCM compounds was downloaded from the TCM database (http://tcm.cmu.edu.tw/); then human Ras protein (PDB ID: 4EPV) crystal structure was obtained from RCSB Protein Data Bank [4].

2.2. Disorder Protein Detection. The disorder plays an important role in drug design; thus we take the sequence generated from Uniprot to predict the disorder region by the Database of Protein Disorder (DisProt: http://www.disprot.org/). The result of prediction was helpful to decide the character of the docking site and the efficacy of the drug [22].

Taking a comparison of the disorder regions and the docking sites could assess the protein-ligand interaction and drug efficacy.

2.3. Molecular Docking. The docking simulation applied on LigandFit module [23] a receptor-rigid docking algorithm program in Discovery Studio 2.5 (DS 2.5) to dock TCM compounds to Ras in the CHARMM force field [24]. The docking site of Ras was identified by the research [3, 4]. After docking, the top three docking scores of the TCM compounds were selected to process the analysis of the hydrophobic interactions by Ligplot [25, 26].

2.4. Molecular Dynamics Simulation. These ligands from candidate complex must be reprepared based on the reference force field [27] of GROMACS 4.5.5 [28] by using SwissParam (http://swissparam.ch/) [29] before applying MD simulation. The Ras protein combines with ligands as the complex goes into the buffer/solution simulation box. With a minimum distance of 1.2 Å from the complex, the cubic box was solvated with the TIP3P water model in which sodium and chloride ion were added to neutralize complex charges. The minimization for complex is on the basis of the steepest descent method for 5,000 steps; then the last structure was transferred to MD simulation. The calculations for electrostatic interactions were based on the particle-mesh
Figure 2: The structure of control and candidate TCM compounds. (a) Saussureamine C, (b) S-allylmercaptocysteine, and (c) Tryptophan.

Figure 3: The docking poses of ligands. (a) The crystal structure of Ras and Rho and the docking site: (b) Saussureamine C, (c) S-allylmercaptocysteine, and (d) Tryptophan.

Ewald (PME) method [30] in which each time step was 2 fs and the numbers of steps were 5,000,000 times. The 100 ps constant temperature (PER ensemble) for equilibration was on the basis of the Berendsen weak thermal coupling method. The total simulation time of MD was 10,000 ps. MD trajectories, RMSD, energy variations, and eigenvector were analyzed using a series of protocols in Gromacs.

3. Results and Discussion

3.1. The Detection of Disorder Protein. The disorder protein is an unstructured protein. For this character, while the docking site is a disorder region, the compounds dock to protein and stabilize the complex with difficulty. In some cited references, [8, 22] also indicate that the disorder region does not consist of any defined domain; thus the drug that can interact with disorder region may have lower side effect than the widespread domain. The disorder region can be defined better as a hard work for drug design than as a bad docking site for selection in our known. The disorder regions are defined as having a disposition of over than 0.5 (Figure 1). In this result, the disposition of important amino acids is less than the threshold; then the ligand docks to the selected site may be appropriate and our results have a weaker effect from disorder protein.

3.2. Molecular Docking. Ranking the result of molecular docking by docking score, the top three TCM compounds can be selected (Table 1). These TCM compounds are Saussureamine C, S-allylmercaptocysteine, and Tryptophan.
Figure 4: Ligplot illustrates the protein-ligand interactions. (a) Saussureamine C, (b) S-allylmercaptocysteine, and (c) Tryptophan. The deep red color of the hydrophobic interactions indicates a high frequency in all ligand interactions.

Table 1: Scoring functions of the top three compounds and the inhibition of Ras.

| Compounds          | Herbs            | -PLP1 | -PLP2 | Dock score |
|--------------------|------------------|-------|-------|------------|
| Saussureamine C    | *Saussurea lappa* Clarke | 35.6  | 35.37 | 196.626    |
| S-Allylmercaptocysteine | *Allium sativum*    | 21.01 | 27.18 | 185.706    |
| Tryptophan         | *Isatis indigotica* Fort. | 41.19 | 44.91 | 184.146    |
extract from the TCM herbs *Saussurea lappa* Clarke, *Allium sativum*, and *Isatis indigotica* Fort., respectively. The top compound, Saussureamine C, is defined as an antiulcer compound [31] and the herb *Saussurea lappa* Clarke can prevent breast cancer cell migration [32], treat heart disease [33, 34], have antihepatotoxic activity [35], and express the killing function of cytotoxic T lymphocytes [36]. The second ranked herb, *Allium sativum*, can antimicrobially [37–39] ameliorate tamoxifen-induced liver injury [40] and with the compound S-allylmercaptocysteine is hepatoprotective and inhibits cancer [41–45]. The third ranked compound, Tryptophan from the herb *Isatis indigotica* Fort., can prevent acute fatal liver failure [46] and make the activation of the differentiation potential for liver progenitor cells [47]. As reported in these literatures, most of these compounds can have an effect on immunity and antihepatotoxic activity. For the above reasons, we suggest that the selected compounds can have effect on Ras.

The structure of the candidate compounds is selected after screening from the TCM database (Figure 2); then the docking poses sign the docking site and the important amino acid on the neighbors by ligands (Figure 3). From this result, we observe Lys117 is defined as the amino acids that can interact with all ligands; therefore we suggest these

---

**Figure 5:** Measures of the MD trajectories. (a) Complex RMSD, (b) ligand RMSD, and (c) the total energy.

**Figure 6:** The variation of RMSD focus on residue of protein.
amino acids may play important roles in a Ras target function.

The hydrophobic interaction can be analyzed by ligplot (Figure 4). This result shows that the amino acids Asp30 and Lys147 can have interactions with the ligands through hydrophobic interactions or hydrogen bonds. These amino acids might be as important amino while the selected compounds have an effect on Ras.

3.3. Molecular Dynamics Simulation. The RMSD and total energy of a complex during MD simulation were recorded (Figure 5). The total energy is in the range of $-430 \sim -438 \times 10^3$ kJ/mol and tends to $-434.5 \times 10^3$ kJ/mol. The amplitude is gentle; then we suggest the interaction for Ras and compounds are finished (or mean balance). Besides S-allymercaptocysteine, the other two compounds do not have large variation. The smaller variation of ligand RMSD indicates the complex will have less interaction and tend to balance. The Saussureamine C has the largest complex RMSD after 3 ns that is presented; the ligand moves away from the docking site recorded in MD.

We analyze RMSF which is the RMSD focus on each residue to detect the variation of protein while with ligand interaction (Figure 6). According to this result, we can find

Figure 7: The PCA-eigenvector between ligand and unbound protein. The projection to the first two PCA-eigenvectors as $x$ and $y$ axes based on the backbone of Ras. The comparison of eigenvector between apo and (a) Saussureamine C, (b) S-allymercaptocysteine, and (c) Tryptophan.
the pick sites of residues are similar between Apo form and protein-ligand interaction. The variation of these sites are different caused from ligand interaction.

The reference-identified eigenvector was used to represent the protein variation [48]. The first two PCA (principal component analysis) eigenvectors would become the $x$- and $y$-axes and make the comparison with apo (unbound protein) find protein variation of the first main character of protein (Figure 7). Up in the figure is the first eigenvectors diffusion between apo and complex. The following figure is matrix from first two eigenvectors. After the comparison, we find complex with S-allylmercaptocysteine is similar to apo then different from other compounds. That is because this complex lost the interaction from compound after 30000 ps; then protein interaction was weaker than others. From this result, eigenvector could help in interaction evolution.

After the structure variation discussion is based on eigenvector, we should focus on the structure variation during
protein-ligand interaction (Figures 8 to 10). In Figure 8(a), there is high percentage occupancy in H bond from Asp30 and Lys117 after MD 1 ns that present these two amino acids may have the function to inhibit the Ras. Figure 8(b) shows the variation between MD 0 ns and 10 ns. From this result, we find the protein has two obvious changes on both position and even composition; then we suggest the structure might make Ras lose the function and be inhibited.

Although the complex of S-allylmercaptocysteine and Ras has higher docking score and a lot of relation references, this complex is not stable. The Asp30 and Lys117 also present the important interaction in Figure 9(a) and some region of the structure has variation in Figure 9(b). From these results, we suggest S-allylmercaptocysteine may have better efficacy from the other protein than Ras to control the liver tumorigenesis and the S-allylmercaptocysteine may have a short term effect on Ras.

The Tryptophan complex interactions were recorded (Figure 10). In Figure 10(a), besides Asp30 and Lys117, the Asp119 plays the important role on interaction before 2 ns. There are some position variations caused from Tryptophan interaction in Figure 10(b).

From these variations found, we suggest Saussureamine C could make the largest force on the inhibition of Ras.

Finally, the pathway definition which is based on the calculation of caver 3.0 to determine the interpath protein path during MD simulation [49] could help find out the ligand moving and the pole provided from protein after interaction (Figure 11). In these pathways, we could find the compounds moving around the docking site then into protein. We suggest the inhibition site of Ras might be around the docking site and from the interaction the Ras will be inhibited.

4. Conclusion

Based on above discussion, we can find the top three TCM compounds Saussureamine C, S-allylmercaptocysteine, and Tryptophan can have an effect on Ras against liver tumorigenesis. Asp30 and Lys117 might present their effects on Ras when compounds bind or interact with protein. Even S-allylmercaptocysteine has a lot of references to identify the efficacy on this disease but the result of simulation indicates this compound may have more effect on the other protein then represent the regulation. Finally, according to the discussion from docking, interaction, and variation, we suggest Saussureamine C might be a best compound to inhibit Ras against liver tumorigenesis.
Figure 11: The pathway of Ras for compounds. (a) Unbound protein, (b) Saussureamine C, (c) S-allylmercaptocysteine, and (d) Tryptophan.
Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Tzu-Chieh Hung, Wen-Yuan Lee, and Kuen-Bao Chen contributed equally to this paper.

Acknowledgments

The research was supported by Grants from the National Science Council of Taiwan (NSC102-2325-B039-001 and NSC102-2221-E-468-027-), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, and 102-Asia-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-D02-102-04), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-004), and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.

References

[1] T. W. Chew, X. J. Liu, L. Liu, J. M. Spitsbergen, Z. Gong, and B. C. Low, “Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models,” Oncogene, vol. 33, no. 21, pp. 2717–2727, 2014.
[2] A. T. Baines, D. Xu, and C. J. Der, “Inhibition of Ras for cancer treatment: the search continues,” Future Medicinal Chemistry, vol. 3, no. 14, pp. 1787–1808, 2011.
[3] J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, and K. M. Shokat, “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions,” Nature, vol. 503, no. 7477, pp. 548–551, 2013.
[4] Q. Sun, J. P. Burke, J. Phan et al., “Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation,” Angewandte Chemie International Edition, vol. 51, no. 25, pp. 6140–6143, 2012.
[5] H.-J. Huang, H. W. Yu, C.-Y. Chen et al., “Current developments of computer-aided drug design,” Journal of the Taiwan Institute of Chemical Engineers, vol. 41, no. 6, pp. 623–635, 2010.
[6] W. I. Tou, S.-S. Chang, C.-C. Lee, and C. Y.-C. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, p. 844, 2013.
[7] C. Y.-C. Chen, “A novel integrated framework and improved methodology of computer-aided drug design,” Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965–988, 2013.
[8] C. Y.-C. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013.
[9] W.-L. Liao and F.-J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013.
[10] C.-C. Lee, C.-H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013.
[11] I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013.
[12] C. Y. C. Chen, “TCM database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico,” PLoS ONE, vol. 6, no. 1, Article ID e15399, 2011.
[13] H.-J. Huang, K.-J. Lee, H. W. Yu et al., “Structure-based and ligand-based drug design for HER 2 receptor,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 1, pp. 23–37, 2010.
[14] W. I. Tou and C. Y.-C. Chen, “Traditional Chinese medicine as dual guardians against hypertension and cancer?” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 3, pp. 299–317, 2012.
[15] S.-C. Yang, S.-S. Chang, and C. Y.-C. Chen, “Identifying HER2 inhibitors from natural products database,” PLoS ONE, vol. 6, no. 12, Article ID e28793, 2011.
[16] C.-Y. Chen and C. Y.-C. Chen, “Insights into designing the dual-targeted HER2/HSP90 inhibitors,” Journal of Molecular Graphics and Modelling, vol. 29, no. 1, pp. 21–31, 2010.
[17] S. S. Chang, H. J. Huang, and C. Y. C. Chen, “High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM database@Taiwan,” Molecular BioSystems, vol. 7, no. 12, pp. 3366–3374, 2011.
[18] S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011.
[19] C.-Y. Chen, Y.-H. Chang, D.-T. Bau et al., “Ligand-based dual target drug design for H1N1: swine flu—a preliminary first study,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 2, pp. 171–178, 2009.
[20] T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “IScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011.
[21] K.-W. Chang, T.-Y. Tsai, K.-C. Chen et al., “iSMART: an integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug design,” Journal of Biomolecular Structure and Dynamics, vol. 29, no. 1, pp. 243–250, 2011.
[22] W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, vol. 19, no. 4, pp. 367–372, 2014.
[23] C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” Journal of Molecular Graphics and Modelling, vol. 21, no. 4, pp. 289–307, 2003.
[24] B. R. Brooks, C. L. Brooks III, A. D. Mackerell Jr. et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009.
[25] R. A. Laskowski and M. B. Swindells, “LigPlot+: multiple ligand-protein interaction diagrams for drug discovery,” Journal of Chemical Information and Modeling, vol. 51, no. 10, pp. 2778–2786, 2011.
[26] A. C. Wallace, R. A. Laskowski, and J. M. Thornton, “LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions,” Protein Engineering, vol. 8, no. 2, pp. 127–134, 1995.
[27] U. D. Priyakumar and A. D. MacKerell, “Comparison of the CHARMM27, AMBER4.1 and BMS nucleic acid force fields via
free energy calculations of base flipping,” *Abstracts of Papers of the American Chemical Society,* vol. 230, pp. U1391–U1392, 2005.

[28] B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl, “GRGAMCS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation,” *Journal of Chemical Theory and Computation,* vol. 4, no. 3, pp. 435–447, 2008.

[29] V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, “SwissParam: a fast force field generation tool for small organic molecules,” *Journal of Computational Chemistry,* vol. 32, no. 11, pp. 2359–2368, 2011.

[30] T. A. Darden and L. G. Pedersen, “Molecular modeling: an experimental tool,” *Environmental Health Perspectives,* vol. 101, no. 5, pp. 410–412, 1993.

[31] M. Yoshikawa, S. Hatakeyama, Y. Inoue, and J. Yamahara, “Saussureamines A, B, C, D, and E, new anti-ulcer principles from Chinese saussureae radix,” *Chemical and Pharmaceutical Bulletin,* vol. 41, no. 5, pp. 214–216, 1993.

[32] Y. K. Choi, S. G. Cho, S. M. Woo et al., “Saussurea lappa clarke-derived costunolide prevents TNF alpha-induced breast cancer cell migration and invasion by inhibiting NF-kappa B activity,” *Evidence-Based Complementary and Alternative Medicine,* vol. 2013, Article ID 936257, 10 pages, 2013.

[33] O. P. Upadhyay, J. K. Ojha, H. S. Bajpai, and A. K. Hathwal, “Study of kustha (Saussurea lappa, clarke) in ischaemic heart disease,” *Ancient Science of Life,* vol. 13, no. 1-2, pp. 11–18, 1993.

[34] T. S. Saleem, N. Lokanath, A. Prasanthi, M. Madhavi, G. Mallika, and M. N. Vishnu, “Aqueous extract of Saussurea lappa root ameliorate oxidative myocardial injury induced by isoproterenol in rats,” *Journal of Advanced Pharmaceutical Technology and Research,* vol. 4, no. 2, pp. 94–100, 2013.

[35] S. Yaeesh, Q. Jamal, A. J. Shah, and A. H. Gilani, “Antihapatotoxic activity of Saussurea lappa extract on D-galactosamine and lipopolysaccharide-induced hepatitis in mice,” *Phytotherapy Research,* vol. 24, supplement 2, pp. S229–S232, 2010.

[36] M. Taniguchi, T. Kataoka, H. Suzuki et al., “Costunolide and dehydrocostus lactone as inhibitors of killing function of cytotoxic T lymphocytes,” *Bioscience, Biotechnology and Biochemistry,* vol. 59, no. II, pp. 2064–2067, 1995.

[37] S. H. A. Seddiek, M. M. El-Shorbagy, H. F. Khatir, and A. M. Ali, “The antitrichomonal efficacy of garlic and metronidazole against *Trichomonas gallinae* infecting domestic pigeons,” *Parasitology Research,* vol. 113, no. 4, pp. 1339–1329, 2014.

[38] Y. Liu, M. Song, T. M. Che et al., “Dietary plant extracts modulate gene expression profiles in ileal mucosa of weaned pigs after an *Escherichia coli* infection,” *Journal of Animal Science,* vol. 92, pp. 2050–2062, 2014.

[39] R. Snowden, H. Harrington, K. Morrill et al., “A comparison of the anti-*Staphylococcus aureus* activity of extracts from commonly used medicinal plants,” *Journal of Alternative and Complementary Medicine,* vol. 20, no. 3, pp. 357–382, 2014.

[40] G. M. Suddek, “Allicin enhances chemotherapeutic response and ameliorates tamoxifen-induced liver injury in experimental animals,” *Pharmaceutical Biology.* In press.

[41] J. Xiao, Y. P. Ching, E. C. Liong, A. A. Nanji, M. L. Fung, and G. L. Tipoe, “Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in *vivo* animal model,” *European Journal of Nutrition,* vol. 52, no. 1, pp. 179–191, 2013.

[42] J. Xiao, R. Guo, M.-L. Fung et al., “Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat model through inhibition of apoptosis and enhancing autophagy,” *Evidence-Based Complementary and Alternative Medicine,* vol. 2013, Article ID 642920, 11 pages, 2013.

[43] J. Xiao, E. C. Liong, M.-T. Ling, Y.-P. Ching, M.-L. Fung, and G. L. Tipoe, “S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice,” *European Journal of Nutrition,* vol. 51, no. 3, pp. 323–333, 2012.

[44] D. Liang, Y. Qin, W. Zhao et al., “S-allylmercaptocysteine effectively inhibits the proliferation of colorectal cancer cells under *in vitro* and *in vivo* conditions,” *Cancer Letters,* vol. 310, no. 1, pp. 69–76, 2011.

[45] Y. Lee, H. Kim, J. Lee, and K. Kim, “Anticancer activity of S-allylmercapto-L-cysteine on implanted tumor of human gastric cancer cell,” *Biological and Pharmaceutical Bulletin,* vol. 34, no. 5, pp. 677–681, 2011.

[46] M. Miyazaki, M. Hardjo, T. Masaka et al., “Isolation of a bone marrow-derived stem cell line with high proliferation potential and its application for preventing acute fatal liver failure,” *Stem Cells,* vol. 25, no. 11, pp. 2855–2863, 2007.

[47] T. Tokiwa, T. Yamazaki, W. Xin et al., “Differentiation potential of an immortalized non-tumorigenic human liver epithelial cell line as liver progenitor cells,” *Cell Biology International,* vol. 30, no. 12, pp. 992–998, 2006.

[48] J. H. Peters and B. L. de Groot, “Ubiquitin dynamics in complexes reveal molecular recognition mechanisms beyond induced fit and conformational selection,” *PLoS Computational Biology,* vol. 8, no. 10, Article ID e1002704, 2012.

[49] E. Chovanova, A. Pavelka, P. Benes et al., “CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures,” *PLoS Computational Biology,* vol. 8, no. 10, Article ID e1002708, 2012.